503 related articles for article (PubMed ID: 28494719)
1. Levodopa in Parkinson's Disease: Current Status and Future Developments.
Tambasco N; Romoli M; Calabresi P
Curr Neuropharmacol; 2018; 16(8):1239-1252. PubMed ID: 28494719
[TBL] [Abstract][Full Text] [Related]
2. Novel Levodopa Formulations for Parkinson's Disease.
Freitas ME; Ruiz-Lopez M; Fox SH
CNS Drugs; 2016 Nov; 30(11):1079-1095. PubMed ID: 27743318
[TBL] [Abstract][Full Text] [Related]
3. Novel formulations and modes of delivery of levodopa.
Poewe W; Antonini A
Mov Disord; 2015 Jan; 30(1):114-20. PubMed ID: 25476691
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
5. Clinical advantages of COMT inhibition with entacapone - a review.
Gordin A; Kaakkola S; Teräväinen H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
7. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.
Annus Á; Vécsei L
Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288
[TBL] [Abstract][Full Text] [Related]
10. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Kestenbaum M; Fahn S
Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
[TBL] [Abstract][Full Text] [Related]
11. IPX066: a novel carbidopa-levodopa extended-release formulation.
Hauser RA
Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
[TBL] [Abstract][Full Text] [Related]
12. Levodopa: past, present, and future.
Hauser RA
Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
[TBL] [Abstract][Full Text] [Related]
13. Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.
Kianirad Y; Simuni T
Curr Neurol Neurosci Rep; 2016 Apr; 16(4):34. PubMed ID: 26898686
[TBL] [Abstract][Full Text] [Related]
14. Novel levodopa formulations in the treatment of Parkinson's disease.
Pilleri M; Antonini A
Expert Rev Neurother; 2014 Feb; 14(2):143-9. PubMed ID: 24428803
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson's disease: is it an improvement on other delivery?
Doggrell SA
Expert Opin Drug Deliv; 2023; 20(9):1189-1199. PubMed ID: 37634938
[TBL] [Abstract][Full Text] [Related]
16. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
[TBL] [Abstract][Full Text] [Related]
17. Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
LeWitt P; Liang GS; Olanow CW; Kieburtz KD; Jimenez R; Olson K; Klepitskaya O; Loewen G
Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):43-50. PubMed ID: 36688497
[TBL] [Abstract][Full Text] [Related]
18. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
[TBL] [Abstract][Full Text] [Related]
19. Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Baek JS; Tee JK; Pang YY; Tan EY; Lim KL; Ho HK; Loo SCJ
Neuromolecular Med; 2018 Jun; 20(2):262-270. PubMed ID: 29696585
[TBL] [Abstract][Full Text] [Related]
20. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
